Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AnaptysBio, Inc. Stock Surged on Wednesday

By Cory Renauer - Feb 7, 2018 at 4:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors eager for more news about the company's anti-allergy candidate have a date to look forward to.

What happened

Shares of AnaptysBio, Inc. (ANAB 0.84%), a clinical-stage biotechnology company, rose 11.1% in midday trading on Wednesday before locking in a 9.4% gain to end the day. Investors appear excited about a recently announced engagement at the annual meeting of the American Academy of Dermatology.

So what 

On Saturday, Feb. 17, AnaptysBio will present data from a phase 2a atopic dermatitis (eczema) trial involving the most advanced candidate the company owns outright, ANB020. The novel new drug candidate inhibits interleukin-33 (IL-33), a mediator of skin-related disorders.

Finger drawing an upward sloping chart in the air.

Image source: Getty Images.

Since IL-33 acts upstream of IL-4 and IL-13, two proteins inhibited by Dupixent, there's a chance ANB020 could be far more effective at stopping inflammation than the recently launched drug. Dupixent is expected to generate peak annual sales exceeding $4 billion for partners Sanofi (SNY 1.96%) and Regeneron (REGN 0.72%).

Now what

AnaptysBio didn't reveal much in its release, but investors can probably look forward to positive data. The company plans to begin a big multi-center trial with between 200 and 300 eczema patients in the first half of the year. Beyond eczema, ANB020 is also in midstage trials for peanut allergies and eosinophilic asthma, both of which should read out in the first half as well.

While AnaptysBio funds development of ANB020 on its own, Tesaro (NASDAQ: TSRO) will fund a phase 3 ovarian-cancer trial with big implications for AnaptysBio. The study, slated to begin in the first half, will test Zejula in combination with TSR-042, a checkpoint inhibitor candidate Tesaro licensed from AnaptysBio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
AnaptysBio
ANAB
$20.47 (0.84%) $0.17
Sanofi Stock Quote
Sanofi
SNY
$51.01 (1.96%) $0.98
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$595.40 (0.72%) $4.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.